BACE1 and Alzheimer disease: Not only does BACE1 initiate Aβ formation, but the observation that BACE1 levels are elevated in AD [97,166-170] provides a direct and compelling reason to develop therapies directed at BACE1 inhibition thus reducing Aβ and its associated toxicities.